Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Jun 1;35(6):488–497. doi: 10.1089/jir.2014.0209

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright 2015, Mary Ann Liebert, Inc.

PMC Copyright notice

FIG. 5. — IFN-α and WY-14643 pretreatment modulates ISG expression at baseline and in response to IFN-α. Pretreatment with IFN-α (2 U/mL) significantly upregulated the baseline expression of ISG15, USP18, and viperin, all of which were significantly reduced with the addition of WY-14643 (A). When cells were treated with high-dose IFN-α (20 U/mL), induction of all 3 ISGs was highest in mock-treated cells and significantly reduced following IFN-α pretreatment (B). The addition of WY-14643 to IFN-α pretreatment significantly increased induction of USP18 at 4 h, ISG15 and viperin at 8 h, and viperin at 24 h. Significant difference between treatment and control, and *significant difference between IFN and IFN plus WY-14643 treatment. Graphs demonstrate an average of 3 experimental replicates (P<0.05, P<0.01).

Inline graphic — IFN-α and WY-14643 pretreatment modulates ISG expression at baseline and in response to IFN-α. Pretreatment with IFN-α (2 U/mL) significantly upregulated the baseline expression of ISG15, USP18, and viperin, all of which were significantly reduced with the addition of WY-14643 (A). When cells were treated with high-dose IFN-α (20 U/mL), induction of all 3 ISGs was highest in mock-treated cells and significantly reduced following IFN-α pretreatment (B). The addition of WY-14643 to IFN-α pretreatment significantly increased induction of USP18 at 4 h, ISG15 and viperin at 8 h, and viperin at 24 h. Significant difference between treatment and control, and *significant difference between IFN and IFN plus WY-14643 treatment. Graphs demonstrate an average of 3 experimental replicates (P<0.05, P<0.01).